CZECRIN
CZECRIN is a Czech national research infrastructure supporting academic clinical trials across 18 partner hospitals and 10 disease networks, operating as the Czech national node of ECRIN-ERIC. It serves academic researchers, hospital trial departments, and rare disease patients through trial coordination, GMP ATMP manufacturing, and regulatory support.
- Company typePrivate
- Founded2014
- HeadquartersBrno, Czechia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What CZECRIN does
CZECRIN is a Czech national research infrastructure that supports academic (non-commercial) clinical trials across the Czech Republic, operating as a distributed network of 18 healthcare facilities and 10 disease-oriented networks (DONETs) covering oncology, epilepsy, stroke, infectious diseases, perinatology, anesthesiology/intensive care, interventional cardiology, neurodegeneration, and pediatrics. Founded on 21 March 2014 by the Ministry of Education, Youth and Sports under the legal umbrella of Masaryk University in Brno, CZECRIN is the official Czech national node of ECRIN-ERIC and is part of the Czech National Roadmap for Large RDI Infrastructures and the ESFRI Roadmap.
Its core platform combines three pillars: a National Centre for Clinical Studies providing methodological, regulatory, monitoring, biostatistics, and data management support; CZECRIN Academy for clinical research education and certification; and the DONET networks coordinating domain-specific trial activity. Underlying infrastructure includes REDCap-based electronic data capture, Phase I clinical trial units for first-in-human studies, GMP-certified ATMP manufacturing facilities (ACIU MUNI and CTEF-cGMP FNUSA-ICRC), and the RaPhe regulatory and pharmacoeconomics advisory unit. Notable outputs include 92 supported clinical studies, 1600+ patients enrolled, 155 scientific publications, 26 H2020 projects, and 4 innovative ATMP products in development, including MyDendrix, which received the first ATMP hospital exemption granted in the Czech Republic.
CZECRIN is funded primarily through public sources — the MŠMT VVI CZECRIN project (LM2023049) and European structural funds (CZECRIN_PRO PACIENTY) — and provides its services as a publicly funded national resource rather than on a commercial basis. Go-to-market is community-led: it acquires collaborators via network building, conference participation, and a public REDCap registration form, with no commercial pricing model. End users are academic clinical researchers, hospital research departments, rare disease patients (especially pediatric oncology), and international research consortia connected through ECRIN-ERIC.
CZECRIN firmographics
Firmographics- Name
- CZECRIN
- Legal name
- Masarykova univerzita
- Website
- https://czecrin.cz
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CZECRIN is a Czech national research infrastructure supporting academic clinical trials across 18 partner hospitals and 10 disease networks, operating as the Czech national node of ECRIN-ERIC. It serves academic researchers, hospital trial departments, and rare disease patients through trial coordination, GMP ATMP manufacturing, and regulatory support.
- Ownership category
- akta.pro rank
CZECRIN industry classification
Industry- Product category
- Clinical Research Infrastructure
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industries
- Investigator & Site Training / GCP Support (HLAGACAF), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Clinical Research Support (CRC/CTA) (EDAOAJAO), Decentralized/Hybrid Trial Enablement (DCT) Platforms (HLACAOAL)
Keywords
Where CZECRIN is headquartered
LocationHeadquarters
- HQ city
- Brno
- HQ country
- Czechia
- HQ region
- Europe
Offices1 record
Markets served
CZECRIN business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Public Research Infrastructure Funding: CZECRIN is funded through Ministry of Education, Youth and Sports (MEYS/MŠMT) via large research infrastructure support programs. It receives state budget funding through project VVI CZECRIN (LM2023049) and European structural funds (CZECRIN_PRO PACIENTY project). The infrastructure does not generate commercial revenue but provides its services as a publicly funded national research resource.
Go-to-market motion1 record
Distribution channels5 records
Marketing channels11 records
CZECRIN product offering
Product offeringCore offering
CZECRIN is a national clinical research infrastructure that provides comprehensive methodological, regulatory, and operational support for non-commercial (academic) clinical trials across the Czech Republic. It operates a distributed network of 18 clinical sites organized into ten disease-oriented networks (DONETs), provides GMP-certified manufacturing for advanced therapy medicinal products (ATMPs), and delivers education and certification through the CZECRIN Academy. As the Czech national node of ECRIN-ERIC, it integrates domestic research capacity into pan-European multi-centre academic trials.
Product overview
CZECRIN is a national clinical research infrastructure that provides comprehensive support for clinical trials throughout their lifecycle. The organization operates as a platform-plus-services model consisting of three main pillars: the National Centre for Clinical Studies (providing methodological and operational support), CZECRIN Academy (education and certification), and Networks (DONETs for disease-specific research networks). The infrastructure includes specialized technological units for GMP-certified ATMP manufacturing (CZECRIN PharmTech, GMP Core Units), advisory services (RaPhe for regulatory and pharmacoeconomics), Phase I clinical units, and connections to European networks via ECRIN-ERIC. CZECRIN supports approximately 18 healthcare facilities, manages 92 clinical trials, participates in 26 H2020 projects, and has enrolled over 1,600 patients in clinical studies.
Differentiator
Problem solved
Functional benefit
Brands
- Národní centrum klinických studií (Clinical Trial National Centre): A national centre providing methodological and practical support for preparation and implementation of clinical trials across the Czech Republic.
- CZECRIN Academy
- DONETs
- Jednotky fáze I (Phase I Units)
- CZECRIN PharmTech / GMP Core Units
- RaPhe (Regulatory Advisory and Pharmacoeconomics Unit)
Products and services
- National Centre for Clinical Studies (Národní centrum klinických studií) Central pillar of CZECRIN providing methodological and practical support for the preparation and implementation of clinical trials across the Czech Republic, including study coordination, start-up support, and regulatory guidance for academic and clinical research teams within the CZECRIN network.
- CZECRIN Academy Educational and certification program for clinical research professionals offering courses and practical training for investigators, coordinators, study nurses, and students to strengthen quality and standards in clinical trials.
- DONETs (Disease-Oriented Networks) Network infrastructure connecting clinical sites and researchers focused on specific disease areas (oncology, epilepsy, stroke, pediatrics, infectious diseases, anesthesiology/intensive care, perinatology, interventional cardiology, neurology, pneumology) to support multi-site academic clinical research within the Czech Republic.
- GMP Core Units (ACIU MUNI and CTEF-cGMP FNUSA-ICRC) Good Manufacturing Practice-certified facilities dedicated to production of Advanced Therapy Medicinal Products (ATMPs) such as cell and gene therapies, supporting non-commercial clinical manufacturing for academic trials.
- Phase I Units (Jednotky fáze I) Specialized facilities for early-phase clinical evaluation including first-in-human studies, providing safe and highly controlled environments for demanding early-phase trials.
- CZECRIN PharmTech Pharmaceutical technology laboratories supporting advanced therapy development and manufacturing activities for clinical research within the CZECRIN network.
- RaPhe - Regulatory Advisory and Pharmacoeconomics Unit Advisory service providing expertise in regulatory strategies, health economics, pharmacoeconomic evaluations, and HTA design, supporting the translation of clinical research findings into cost-effective healthcare interventions.
- Expertise and Services (Feasibility, Monitoring, Statistics, Data Management, Methodology) Comprehensive support package covering feasibility assessments, study preparation, monitoring, biostatistics, electronic data management (REDCap), methodology, and consultations for clinical research projects across the network.
- MyDendrix Cellular immunotherapy (dendritic cell-based) developed through academic research within the CZECRIN/CREATIC ecosystem for pediatric and adolescent patients with high-risk tumors, granted the first hospital exemption for an Advanced Therapy Medicinal Product in the Czech Republic.
Quantifiable outcome
- 1600+ patients enrolled in clinical trials through the CZECRIN network
- +4 more outcomes
Companies that use CZECRIN
Customer profileNamed customers17 records
Segments4 records
Ideal customer profiles3 records
CZECRIN technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
CZECRIN partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- ECRIN-ERIC (European Clinical Research Infrastructure Network)coreCZECRIN is the Czech national node of ECRIN-ERIC, enabling integration of Czech clinical research capacity into the pan-European research infrastructure. Through this membership, Czech researchers can participate in and coordinate international multi-centre non-commercial clinical trials. CZECRIN represents the Czech Republic with full membership in ECRIN-ERIC and is part of the ESFRI Roadmap.
- Masaryk University (MUNI)coreMasaryk University is the host institution and legal entity of CZECRIN. Established by decision of the Ministry of Education, Youth and Sports, with Masaryk University as the host and St. Anne's University Hospital as the founding partner. The university provides institutional infrastructure, administrative support, and academic research environment for CZECRIN operations.
- FNUSA - St. Anne's University Hospital in BrnocoreFNUSA is the founding partner of CZECRIN and home to the ICRC (International Center for Clinical Trials). It provides essential support in clinical site network coordination, technical and administrative services. FNUSA also hosts CTEF-cGMP manufacturing unit and is a national reference centre for rare neurological diseases through ERN-RND.
- CREATIC (Centre of Excellence for Advanced Therapy and Immunotherapy)coreCZECRIN is an integral part of the CREATIC Centre of Excellence at Masaryk University's Faculty of Medicine. CREATIC focuses on research, development, and GMP manufacturing of ATMPs (cell and gene therapies) for patients with rare and serious diseases. CZECRIN supports the clinical trial and regulatory components within this ecosystem.
- ERN EpiCARE (European Reference Network for Rare and Complex Epilepsies)minorCZECRIN | EPI network participates in ERN EpiCARE, connecting Czech epileptology centres with European reference centres for rare epilepsies. The network also collaborates with ERN-RND for neurodegenerative diseases.
- ERN-RND (European Reference Network for Rare Neurological Diseases)minorCZECRIN | NEURODEGEN network is established at FNUSA, which is a member of ERN-RND and acts as a national reference centre for rare neurodegenerative disorders. The network contributes to the ERN-RND Registry and European data-sharing initiatives.
- Motol University Hospital (FN Motol)minorMotol University Hospital is a major clinical trial site and member of CZECRIN. Its Clinical Trials Department provides administrative support for commercial and academic studies and works closely with CZECRIN on trial coordination.
- Masaryk Institute of Oncology (MOÚ)coreKey partner of CZECRIN hosting the Centre for Precision Oncology and leading the GENESIS national molecular tumor board platform. It is a key centre for precision oncology clinical trials and coordinates the GENESIS project connecting 10 oncology centres.
- IKEM - Institute for Clinical and Experimental MedicineminorIKEM is a member of the CZECRIN network, contributing specialized clinical and research capacity in cardiovascular and transplant medicine.
- University Hospital Brno (FN Brno)minorFN Brno provides a Clinical Trials Department with administrative support across hospital clinics, managing contracts, budgets, payments, and study billing across all its departments.
- University Hospital Ostrava (FN Ostrava)minorPart of CZECRIN since 2016, FN Ostrava's Centre for Clinical Studies serves as a link between study sponsors and investigators, functioning as administrative, financial, and control authority for clinical trials.
- General University Hospital Prague (VFN)minorVFN's Clinical Trials and Research Department provides comprehensive administrative and professional support for clinical trial initiation and implementation, including academic IIT projects.
- European Molecular Tumour Board Network (EMTBN)minorThe GENESIS project within CZECRIN | ONCO collaborates with EMTBN as part of international precision oncology data sharing and standardization efforts.
- PRIME ROSE (PRecisIon Cancer MEdicine RepurpOsing SystEm)minorInternational consortium for precision cancer medicine repurposing using pragmatic clinical trials. The GENESIS project collaborates with PRIME ROSE on data sharing and treatment approach analysis.
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
CZECRIN competitors and assessment
Company assessmentBroad incumbents
- ICON plc: Major global CRO offering full-service clinical development, laboratory, and consulting services. Comparable in trial management, regulatory affairs, and biostatistics capabilities, but commercially oriented and far larger in scale than CZECRIN.
- IQVIA: Global commercial CRO and clinical trial services provider. Comparable in delivering multi-centre trial coordination, monitoring, biostatistics, and regulatory services — but operating commercially at vastly larger scale and serving pharma rather than academia.
- Medpace: Mid-to-large global CRO with therapeutic-area specialisation in oncology, cardiology, and rare disease. Comparable in CRO model and therapeutic-area focus, though operating commercially and serving industry sponsors.
Direct peers
- ECRIN-ERIC: European Clinical Research Infrastructure Network, the pan-European umbrella of which CZECRIN is the Czech national node. ECRIN coordinates multinational non-commercial clinical trials across Europe; CZECRIN performs the same function at the national level.
- F-CRIN (French Clinical Research Infrastructure Network): France's national ECRIN-ERIC node, structurally analogous to CZECRIN — multi-thematic clinical trial coordination network with disease-oriented components, investigator training, and EU project participation. Direct national-node peer.
- NIHR Clinical Research Network (UK): UK's nationally funded clinical research delivery network supporting trials across the NHS. Comparable to CZECRIN in providing investigator training, site coordination, and study delivery infrastructure for academic and industry-sponsored trials.
- KKS / KKSN (Koordinierungszentren für Klinische Studien, Germany): Network of German academic clinical trial coordination centres, the German ECRIN-ERIC equivalent. Provides methodological, regulatory, and operational support for academic trials — directly comparable mission, structure, and funder relationship.
Emerging players
- BBMRI-ERIC: European biobanking research infrastructure, partnered with CZECRIN. Comparable in ESFRI-roadmap status and national-node model, but focused on biosamples and data rather than trial delivery.
- EATRIS-ERIC: European Research Infrastructure for Translational Medicine, a sibling ESFRI infrastructure with which CZECRIN collaborates. Shares the European research-infrastructure model and overlapping investigator base, though focused on translational rather than clinical-trial delivery.
Others
- ACRP (Association of Clinical Research Professionals): Global non-profit providing clinical research professional certification and training. Comparable to CZECRIN Academy's education and certification mission, although ACRP is a membership/certification body rather than a trial-delivery infrastructure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CZECRIN social profiles
Digital presenceCZECRIN financial estimates
Financial estimateRevenue estimate
Valuation estimate
CZECRIN leadership team
Management profileNumber of profiles
Profiles1 record
CZECRIN funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CZECRIN M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CZECRIN
What does CZECRIN do?
CZECRIN is a national clinical research infrastructure that provides comprehensive methodological, regulatory, and operational support for non-commercial (academic) clinical trials across the Czech Republic. It operates a distributed network of 18 clinical sites organized into ten disease-oriented networks (DONETs), provides GMP-certified manufacturing for advanced therapy medicinal products (ATMPs), and delivers education and certification through the CZECRIN Academy. As the Czech national node of ECRIN-ERIC, it integrates domestic research capacity into pan-European multi-centre academic trials.
Is CZECRIN a public or private company?
CZECRIN is a private company. It is classified as state government owned and is currently operating.
When was CZECRIN founded?
CZECRIN was founded in 2014. It employs 11 to 50 people.
Where is CZECRIN based?
CZECRIN is headquartered in Brno, Czechia, in the Europe region.
How does CZECRIN make money?
One revenue line is on record: public Research Infrastructure Funding.
Who are CZECRIN's main competitors?
Broad incumbents on record are ICON plc, IQVIA and Medpace. Direct peers are ECRIN-ERIC, F-CRIN (French Clinical Research Infrastructure Network), NIHR Clinical Research Network (UK) and KKS / KKSN (Koordinierungszentren für Klinische Studien, Germany). Emerging players are BBMRI-ERIC and EATRIS-ERIC. ACRP (Association of Clinical Research Professionals) is listed as an others.
Does CZECRIN have an API?
No public API is recorded for CZECRIN.
What industry is CZECRIN in?
CZECRIN's product category is Clinical Research Infrastructure. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGACAF, Investigator & Site Training / GCP Support. Its NAICS code is 54171 and its SIC code is 8000.